RAD-140 is studied for non-steroidal selective receptor modulator activity at androgen receptor binding sites, MK-677 for growth hormone secretagogue properties via GHS-R1a receptor engagement and downstream IGF-1 axis signalling, and YK-11 for proposed interactions with myostatin-related signalling pathways. Combined research protocols allow investigators to examine how these three distinct mechanisms may interact within shared experimental models examining body composition and growth-related signalling.

Cell-based receptor binding assays for RAD-140, growth hormone and IGF-1 pathway signalling measurements for MK-677, and myostatin-related gene expression assays (such as follistatin and myostatin pathway markers in myoblast or muscle cell models) for YK-11 are standard methods for studying this three-compound combination, typically compared across single-compound and combined-compound treatment arms relative to vehicle controls.

Factorial or staggered experimental designs incorporating single-compound, paired-compound, and full three-compound treatment arms allow researchers to isolate the contribution of each compound and identify any combination-specific effects on selected receptor and growth signalling endpoints, a standard approach when studying multi-pathway compound combinations.